Novartis planning submissions for secondary progressive MS candidate

Newly published data in The Lancet from the Phase III EXPAND trial showed that secondary progressive multiple sclerosis (SPMS) candidate siponimod (BAF312) from Novartis AG (NYSE:NVS; SIX:NOVN) reduced

Read the full 288 word article

User Sign In